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myeloma cells
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1 Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA, 2 Section of Hematology and
Oncology, Evans Department of Medicine, Boston Medical Center, Boston, MA, USA
Stimulation of cAMP signaling induces apoptosis in glucocorticoid-sensitive and
resistant CEM leukemic and MM.1 multiple myeloma cell lines, and this effect
is enhanced by dexamethasone in both glucocorticoid-sensitive cell types and in
glucocorticoid-resistant CEM cells. Expression of the mRNA for the glucocorticoid
receptor alpha (GR) promoters 1A3, 1B and 1C, expression of mRNA and protein for
GR, and the BH3-only proapoptotic proteins, Bim and Bad, and the phosphorylation
state of Bad were examined following stimulation of the cAMP and glucocorticoid
signaling pathways. Expression levels of GR promoters were increased by cAMP and
glucocorticoid signaling, but GR protein expression was little changed in CEM and
decreased in MM.1 cells. Stimulation of these two signaling pathways induced Bim
in CEM cells, induced Bad in MM.1 cells, and activated Bad, as indicated by its
dephosphorylation on ser112, in both cell types. This study shows that leukemic and
multiple myeloma cells, including those resistant to glucocorticoids, can be induced to
undergo apoptosis by stimulating the cAMP signaling pathway, with enhancement by
glucocorticoids, and the mechanism by which this occurs may be related to changes in
Bim and Bad expression, and in all cases, to activation of Bad.
Keywords: cAMP signaling, glucocorticoid signaling, Bim, Bad, leukemia, multiple myeloma, glucocorticoid
receptors, phosphodiesterases
INTRODUCTION
Glucocorticoids remain a central component of all therapeutic regimens used to treat leukemia
and multiple myeloma (Ploner et al., 2005; Sionov et al., 2008; Bhadri et al., 2012). However,
about 20% of patients demonstrate resistance to glucocorticoids and do not respond to treatment,
and invariably, of those that do respond, many develop resistance to glucocorticoids later during
treatment, causing them to relapse, with a very poor prognosis (Haarman et al., 2003; Frankfurt
and Rosen, 2004; Schmidt et al., 2004; Ploner et al., 2005; Sionov et al., 2008; Bhadri et al., 2012).
The molecular basis of glucocorticoid resistance is not fully understood. A number of studies using
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in vitro model systems have suggested that it may be
associated with a decrease in the expression or alteration of the
glucocorticoid receptor (GR), such that the steps normally carried
out by the GR that lead to therapeutic beneﬁt are muted (Moalli
and Rosen, 1994; Gaynon and Carrel, 1999; Schmidt et al., 2004,
2006; Ploner et al., 2005); however, at least one study ﬁnds no
correlation with GR expression or function, but ﬁnds instead a
correlation with the profound attenuation of the induction of the
BH3-only pro-apoptotic protein, Bim (Bachmann et al., 2005).
Studies using acute lymphocytic leukemic (ALL) cells obtained
from patients, as well as 15 T-ALL cell lines grown directly
from patients’ cells without prior drug exposure in culture, also
indicated that resistance could not be attributed to mutations
in GR or variations in levels of its expression (Tissing et al.,
2006; Bachmann et al., 2007; Beesley et al., 2009). We found
that stimulation of the cAMP signaling pathway can overcome
glucocorticoid resistance in chronic lymphocytic leukemia (CLL)
cells, and in the ALL cell line, CCRF-CEM (Tiwari et al., 2005;
Lerner and Epstein, 2006; Dong et al., 2010). The mechanism
by which this synergistic eﬀect between stimulation of the
cAMP and glucocorticoid signaling pathways occurs, to induce
apoptosis of glucocorticoid resistant cells, is, however, still not
fully understood. The purpose of this study is to examine the
mechanism(s) by which cAMP and glucocorticoid signaling
synergize to induce apoptosis of leukemic and multiple myeloma
cells.
With respect to leukemia, it appears that the BH3-only
pro-apoptotic proteins, Bim and Bad, may be very critical
regulators of apoptosis of these cells. In a DNA microarray
analysis to uncover genes important in glucocorticoid-induced
apoptosis of leukemic cells, Bim was identiﬁed as one of
the proteins whose expression was most upregulated (Wang
et al., 2003). Additionally, studies with mice made deﬁcient
for the production of Bim indicate that Bim plays a key role
in mediating apoptosis of B and T lymphocytes (Hildeman
et al., 2002; Mouhamad et al., 2004). And silencing of the
Bim gene with RNAi inhibits glucocorticoid-induced apoptosis
of leukemic cells (Abrams et al., 2004). Bim exists as three
alternate spliced forms, a short form, BimS, a long form,
BimL, and an extra long form, BimEL. Both the turnover
and activation of BimEL have been shown to be regulated
by its phosphorylation by the MAP Kinases, ERK 1/2 (Ley
et al., 2004) and JNK (Putcha et al., 2003). Additionally,
studies have shown that the expression of Bim at the gene
level is under direct control of the Forkhead transcription
factor, FOXO (FKHR; Dijkers et al., 2000). FOXO itself can be
phosphorylated and inhibited by the growth promoting kinase
PKB/Akt (Burgering and Medema, 2003). PKB/Akt was shown
to be inhibited in lymphoma cells by stimulating the cAMP
pathway with phosphodiesterase4 (PDE4) inhibitors (Smith
et al., 2005), and a similar eﬀect was also seen in mouse
embryo ﬁbroblasts (Kuiperij et al., 2005). Hence, stimulating
the cAMP pathway and inhibiting PKB/Akt, would be expected
to disinhibit FOXO and drive the expression of Bim. And
indeed, it was shown that stimulation of the cAMP and
glucocorticoid pathways in mouse S49 lymphoma and human
CCRF-CEM leukemia cells resulted in a synergistic increase
in the expression of Bim (Zhang and Insel, 2004). Bad also
appears to be a key player in the regulation of lymphoid
cell apoptosis. The activity of Bad is largely controlled by its
state of phosphorylation. Studies with interleukin-3 dependent
lymphoid cells have shown that when Bad is phosphorylated
it is sequestered into an inactive complex with the chaperone
protein, 14-3-3. Upon stimulation of its dephosphorylation, it
dissociates from 14-3-3 and can then act to initiate apoptosis
(Chiang et al., 2001). In cells from patients with CLL,
stimulation of the cAMP pathway with the PDE4 inhibitor
rolipram led to activation of the protein phosphatase 2A,
which dephosphorylated Bad, on its ser112 residue, resulting
in increased apoptosis of the leukemic cells (Moon and Lerner,
2003).
We showed previously that inhibitors of PDE4 induce
apoptosis of primary CLL cells and synergize with
glucocorticoids in doing so (Tiwari et al., 2005). Using
glucocorticoid-sensitive and resistant CCRF-CEM leukemic
cell lines that we established previously (Tiwari et al., 2005),
and established glucocorticoid-sensitive and resistant multiple
myeloma cell lines (Greenstein et al., 2003), we examined the
eﬀects of stimulation of these two signaling pathways on these
glucocorticoid-sensitive and resistant cell types, in relation to
their eﬀects on the expression of the mRNA for the GR alpha
promoters 1A3, 1B and 1C, expression of mRNA and protein
for GR, and the BH3-only proapoptotic proteins, Bim and Bad,
and the phosphorylation state of Bad, as a means to examine the
mechanism for the synergy between stimulation of the cAMP
and glucocorticoid signaling pathways on apoptosis of these
cells.
MATERIALS AND METHODS
Materials
Dexamethasone, hydrocortisone, rolipram, forskolin, and
1,9-dideoxyforskolin were obtained from Biomol (Plymouth
Meeting, PA, USA). Phenazine methosulfate (PMS) and
protease inhibitor cocktail for use with mammalian cell and
tissue extracts were from Sigma-Aldrich (St. Louis, MO, USA).
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] (MTS) was from
Promega (Madison, WI, USA). Primary rabbit polyclonal
antibodies directed against GR, Bim, Bad, and S112 phospho-
Bad were obtained either from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), Cell Signaling Technologies (Danvers, MA,
USA), Biosource International (Camarillo, CA, USA), or Zymed
Laboratories (South San Francisco, CA, USA). The speciﬁc
antibodies used were: GR, Santa Cruz sc-8992; Bim, Santa Cruz
sc-11425 and Zymed 38-6500; Bad, Santa Cruz sc-7869 and
Cell Signaling Technologies 9292; phospho-Bad, Santa Cruz
sc-7998-R, Cell Signaling Technologies 9291 and Biosource
International 44-522. Primary rabbit monoclonal antibody
directed against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was obtained from Cell Signaling Technologies.
Anti-Rabbit IgG-horseradish peroxidase was obtained from GE
Healthcare (Piscataway, NJ, USA).
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Cell Culture
Glucocorticoid-sensitive (CEM-S2) and glucocorticoid-resistant
(CEM-R8) CCRF-CEM T leukemic cell lines were isolated
as described previously (Tiwari et al., 2005). Established
glucocorticoid-sensitive (MM.1S) and glucocorticoid-resistant
(MM.1R) cell lines (Greenstein et al., 2003) were also obtained
for this study. CEM and MM.1 cells were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin
(all from Invitrogen, Carlsbad, CA, USA), at 37◦C in a humidiﬁed
atmosphere of 95% air and 5% CO2.
MTS Assay
MTS assays were conducted as described previously (Dong et al.,
2010, 2015). CEM and MM.1 cells were plated in triplicate at a
density of 3 × 104 cells/well in 96-well ﬂat-bottom tissue culture
plates in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml
penicillin, 100µg/ ml streptomycin, in a total volume of 0.1 ml of
fresh medium containing the test reagents or vehicle as indicated.
Following incubation at 37◦C for 72 h, 20 ul of a combined
solution of MTS (2 mg/ml)/PMS (0.92 mg/ml; 20:1, mixed
immediately before use) was added to each well, and the plates
incubated for an additional 2 h at 37◦C, protected from light,
following which the absorbency (OD) of the formazan product
formed was determined at 492 nm using a microtiter plate reader
(Titertek Multiscan Plus model MK II from Labsystems). The
assay was optimized by seeding diﬀerent amounts of cells at zero
time, and determining changes in cell number over 24, 48, and
72 h times to establish ranges of linearity. All assays were done
under conditions that maintained them in these linear ranges.
With the exception of dexamethasone, all reagents tested were
dissolved in DMSO and diluted into the cell culture medium
such that the ﬁnal concentration of DMSO in the assay was 0.1%.
Percent cell viability is proportional to the amount of formazan
product formed and was calculated as follows: (OD test sample –
OD blank)/(OD control – OD blank) × 100, where blank refers
to plate wells where media, vehicle, and test reagents were added,
as appropriate, but cells were omitted.
Quantitative Real-Time RT-PCR
Quantitative real-time RT-PCR (qRT-PCR) was performed as
described previously (Dong et al., 2010, 2015). Total RNA was
isolated from cells incubated at diﬀerent times as indicated, using
RNeasy mini kits (Qiagen, Valencia, CA, USA) according to
the manufacturer’s instructions. cDNA was synthesized using
M-MLV reverse transcriptase (Promega, Madison, WI, USA).
Primers were designed using ABI Primer Express Software
v3.0. and synthesized by Integrated DNA Technologies, Inc.
(Coralville, IA, USA) The primers used for the diﬀerent mRNA
expressions analyzed are presented in Table 1. qRT-PCR was
performed using an ABI 7500 fast system and data analyzed using
7500 fast system SDS software v3.0.
Western Immunoblot Analysis
Western immunoblot analysis was performed as described
previously (Dong et al., 2010, 2015; Vang et al., 2013). CEM
TABLE 1 | Sequences of primers used for quantitative real-time RT-PCR.
Name Sequence
GR Forward: AGCCATTGTCAAGAGCGAAC
Reverse: TGATTGGTGATGATTTCAGCTA
GR1A3 Forward: GCCTGGCTCCTTTCCTCAA
Reverse: CAGGAGTTAATGATTCTTTGGAGTCC
GR1B Forward: GCCCAGATGATGCGGTG
Reverse: TCTACCAGGAGTTAATGATTCTTTGGA
GR1C Forward: GGGAACTGCGGACGGTG
Reverse: GGAGTTAATGATTCTTTGGAGTCCA
Bim Forward: ACAGAGCCACAAGACAGGAG
Reverse: CCATTGCACTGAGATAGTGGTTG
Bad Forward: CGGAGGATGAGTGACGAGTT
Reverse: CCACCAGGACTGGAAGACTC
RPL19 Forward: GAGAAACGGCTGGATGATAGC
Reverse: TGGTTAGGCTCTTGTACTACTGG
and MM.1 cells were centrifuged at 300 × g for 5 min at
the appropriate time points after treatments, washed twice with
ice-cold PBS, and lysed in 100 µl RIPA buﬀer (50 mM Tri-
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25%
Na-deoxycholate, and 1:100 protease inhibitor cocktail). Protein
concentration was determined using a Micro BCA Protein Assay
Kit (Pierce, Rockford, IL, USA). Equal amounts of protein were
loaded and run on 12% SDS-PAGE gels. Proteins were then
transferred onto Immobilon-p Transfer Membrane (Millipore).
Membranes were blocked with 5% non-fat dry milk in Tris-
buﬀered saline for 1 h at room temperature and probed
with primary antibody overnight at 4◦C, washed three times
with TBS-T buﬀer, and incubated with horseradish peroxidase-
conjugated secondary antibody at a ﬁnal dilution of 1:5000 and
then washed three more times. Proteins were visualized with
SuperSignal West Femto maximum Sensitivity Substrate (Pierce,
Rockford, IL, USA) and densities of the bands determined
using either a UVP BioImaging system (St. Upland, CA,
USA) or a Gene-snap Bioimaging system (Syngene, Frederick,
MD, USA) with associated software. Blots were stripped and
reprobed with GADPH antibody for normalization. Quantitative
comparisons of protein expression following diﬀerent treatments
were calculated by determining the ratio of the target protein
band density/GAPDH band density for each given treatment
and time, divided by the ratio of the target protein band
density/GAPDH band density for the untreated control for that
given time.
RESULTS
cAMP Signaling Induces Apoptosis of
Both Glucocorticoid-Sensitive and
Glucocorticoid-Resistant CEM and MM.1
Cell Lines
Established glucocorticoid-sensitive and glucocorticoid-resistant
CEM and MM.1 cell lines were maintained in culture and
the eﬀects of stimulation of the glucocorticoid and cAMP
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signaling pathways on viability of these cells was examined.
As shown in Figure 1A, stimulation of the glucocorticoid
signaling pathway by dexamethasone (1 µM) decreased the
viability of the glucocorticoid-sensitive CEM-S2 cells by 78% after
72 h, but had no eﬀect on the viability of the glucocorticoid-
resistant CEM-R8 cells (Figure 1B). In contrast, stimulation of
the cAMP signaling pathway by the adenylyl cyclase activator
forskolin (10 µM) plus the PDE4 inhibitor rolipram (10 µM)
decreased the viability of both CEM-S2 and CEM-R8 cells (40
and 30% inhibition, respectively, Figures 1A,B). Additionally,
these eﬀects of forskolin and rolipram on cell viability were
greatly potentiated by dexamethasone, resulting in 98 and
95% decrease in cell viability of CEM-S2 and CEM-R8 cells
respectively when both the cAMP and glucocorticoid signaling
pathways were stimulated concurrently (Figures 1A,B). Very
similar to results seen with CEM leukemic cells, stimulation of
the glucocorticoid signaling pathway by dexamethasone (1 µM)
also decreased the viability of the glucocorticoid-sensitive MM.1S
multiple myeloma cells by 78% after 72 h (Figure 1C), and
had no eﬀect on the viability of the glucocorticoid-resistant
MM.1R cells (Figure 1D). Additionally, also similar to CEM
cells, stimulation of the cAMP signaling pathway by forskolin
(10 µM) and rolipram (10 µM) greatly decreased the viability
of both MM.1S cells (78% inhibition) and MM.1R cells (56%
inhibition). The eﬀects of forskolin and rolipram on cell
viability were potentiated by the addition of dexamethasone in
MM.1S cells, where inhibition of cell viability was increased
from 78 to 92% (Figure 1C), although, unlike glucocorticoid-
resistant CEM-R8 cells, there was only a small potentiation in
glucocorticoid-resistant MM.1R cells where inhibition of cell
FIGURE 1 | Effect of dexamethasone, rolipram, and forskolin on viability of glucocorticoid-sensitive and glucocorticoid-resistant CEM and MM.1
cells. (A) CEM-S2 cells, (B) CEM-R8 cells, (C) MM.1S cells, and (D) MM.1R cells were treated with 1 µM dexamethasone (Dex), 10 µM rolipram plus 10 µM
forskolin (R+F), or 1 µM dexamethasone plus 10 µM rolipram plus 10 µM forskolin (R+F+Dex) for 72 h. Cell viability was then determined by the MTS method. Data
represent the mean ± SD of at least two independent experiments assayed in triplicate.
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viability was increased from 56 to 60% (Figure 1D). Analysis
of the cells following these treatments by direct microscopic
visualization revealed cell loss and cell shrinking, and by
gel analysis of isolated genomic DNA revealed DNA ladder
patterns, indicating that loss of cell viability is consistent
with apoptosis of the cells (data not shown). These results
indicate that the glucocorticoid-resistant CEM-R8 leukemic and
MM.1R multiple myeloma cell lines, while completely resistant
to the eﬀects of glucocorticoids, are still able to be killed by
stimulation of the cAMP signaling pathway. Further, stimulation
of the cAMP and glucocorticoid signaling pathways together
act synergistically to decrease viability of both glucocorticoid-
sensitive and resistant CEM cells and glucocorticoid-sensitive
MM.1 cells.
Forskolin Acts through Stimulation of the
cAMP Signaling Pathway
Inasmuch as forskolin has been reported to produce eﬀects
independent of its activation of adenylyl cyclase (Ding and
Staudinger, 2005; Riddell et al., 2013; Angel-Chavez et al., 2015),
we compared forskolin with 1,9-dideoxyforskolin, an analog of
forskolin that does not stimulate adenylyl cyclase, but maintains
many of the other pleiotropic eﬀects of forskolin, for their
ability to synergize with glucocorticoids to induce cell death
in CEM cells. As seen in Figure 2, neither forskolin nor 1,9-
dideoxyforskolin by themselves have any eﬀect on viability of
CEM-S2 or CEM-R8 cells; however, forskolin synergizes with
hydrocortisone to induce cell death in CEM-S2 and CEM-
R8 cells, whereas 1,9-dideoxyforskolin does not. This indicates
that forskolin is most likely acting through stimulation of the
cAMP signaling pathway, and not through other pleiotropic
eﬀects.
Expression of the Glucocorticoid
Receptor Alpha (GR) Gene Product is
Little Changed by Stimulation of the
cAMP and Glucocorticoid Signaling
Pathways in CEM cells and Greatly
Downregulated in MM.1 Cells
RNA transcript and protein expression for the alpha form of
the GR was examined by qRT-PCR and Western blot analysis
in response to stimulation of the cAMP and glucocorticoid
signaling pathways. As shown in Figures 3A,B, stimulation of
the cAMP signaling pathway by forskolin and rolipram and the
glucocorticoid pathway by dexamethasone induced transcription
of the mRNA for GR in CEM cells. When protein product
for GR was analyzed by Western blot, however, little change
was seen in its expression following stimulation of the cAMP
signaling pathway, except for some (1.3–2.3-fold) induction at
the late, 24 h time point, for both glucocorticoid-sensitive and
resistant CEM cells, and this induction of GR was attenuated
by simultaneous stimulation of the glucocorticoid pathway
with dexamethasone (Figures 3C,D). The doublets seen in the
Western blot immunostaining for GR alpha (Figures 3C,D,F)
of Mr 94 kDa and Mr 91 kDa, represent the two forms of
GR alpha, termed GR-A and GR-B, produced by alternative
translation of the GR alpha gene, with the 91 kDa form produced
from an internal ATG codon corresponding to met27 (Yudt
and Cidlowski, 2001). In MM.1S cells, cAMP and glucocorticoid
signaling produced either no change or small increases in mRNA
for GR (Figure 3E), but GR protein was greatly diminished in
response to dexamethasone treatment, and further diminished to
the point of being nearly absent at the 48 and 72 h time points,
when both the glucocorticoid and cAMP signaling pathways
were stimulated together (Figure 3F). The MM.1R cell line
has been reported to mainly express truncated forms of the
GR with non-functional hormone binding domains, and as
such, produces very little full length GR product (Moalli et al.,
1992). Consistent with this, we were unable to detect any
expression for GR in MM.1R cells under any conditions (data not
shown).
Stimulation of the cAMP Signaling
Pathway Induces the 1A, 1B, and 1C
Promoters for GR in CEM and MM.1 Cells
In humans, the GR is transcribed from at least three diﬀerent
promoters, termed 1A, 1B, and 1C, with 1A further exhibiting
three diﬀerent splice sites designated 1A1, 1A2, and 1A3 (Yudt
and Cidlowski, 2002). Using primers speciﬁc for the 1A3, 1B,
and 1C promoter regions, we examined the eﬀect of stimulation
of the cAMP signaling pathway on expression of the three GR
promoters. As seen in Figures 4Ai,Bi, expression of the 1A3
promoters for CEM-S2 and CEM-R8 cells were highly induced
by stimulation of cAMP signaling, and this was potentiated by
glucocorticoid signaling to yield inductions of the 1A3 promoter
of as much as≈30–120-fold by 24 h. The 1B and 1C promoters in
CEM cells were also induced 6–8-fold at 24 h by combined cAMP
and glucocorticoid signaling (Figures 4Aii,iii,4Bii,iii). The 1A3
promoter was transiently induced by forskolin and rolipram
in MM.1S cells. A 150-fold induction of the 1A3 promoter
was seen in MM.1S cells at 2 h after forskolin and rolipram
treatment, after which the enhanced expression diminished to
only sixfold by 6 h (Figure 4Ci), and expression of 1A3 was
then undetectable at 24 and 48 h (not shown). Dexamethasone
by itself had little eﬀect on the expression of the 1A3 promoter
in MM.1S cells, but, as with protein expression of the GR itself,
dexamethasone attenuated the induction of the 1A3 promoter
by forskolin and rolipram (Figure 4Ci insert). The eﬀect of
cAMP signaling on expression of the 1B and 1C promoters
in MM.1S cells was quite diﬀerent from that of the 1A3
promoter. Forskolin and rolipram had no eﬀect on expression
of the 1B and 1C promoters until 48 h, at which time they
induced expression of both of these promoters by 4–5-fold.
Dexamethasone by itself also had no eﬀect on expression of
the 1B and 1C promoters until 48 h, at which time it induced
expression of both of these promoters also by about ﬁvefold.
However, whereas dexamethasone attenuated the induction of
the 1A3 promoter by forskolin and rolipram, in contrast, it
greatly potentiated the induction of the 1B and 1C promoters,
resulting in 19–26-fold induction of both of these promoters
(Figure 4Cii,iii).
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FIGURE 2 | Effect of 1,9-dideoxyforskolin on CEM cells. Cell viability of CEM-S2 cells (A) and CEM-R8 cells (B). Cells were treated with 10 µM forskolin (Fsk) or
10 µM 1,9-dideoxyforskolin (dFsk) in the presence or absence of 10 µM hydrocortisone (HC) for 72 h. After treatment, cell viability was determined by MTS assay.
Data represent the mean ± SD of at least two independent experiments assayed in triplicate.
Bim Expression is Induced by
Stimulation of the cAMP and
Glucocorticoid Signaling Pathways in
Glucocorticoid-Sensitive and Resistant
CEM Cells and in
Glucocorticoid-Sensitive MM.1 Cells, but
not in Glucocorticoid-Resistant MM.1
Cells
RNA transcript and protein expression for the BH3-only
proapoptotic protein, Bim, was examined by qRT-PCR and
Western blot analysis in response to stimulation of the cAMP and
glucocorticoid signaling pathways. As shown in Figures 5A,B,
mRNA expression for Bim is induced several fold by cAMP
and glucocorticoid signaling in both CEM-S2 and CEM-R8
cells, at all time points examined, and this induction is greatly
potentiated, yielding inductions of ≈20–60-fold, when both
signaling pathways are stimulated together.
Expression of Bim protein in response to stimulation of
these signaling pathways reﬂected the changes seen in Bim
mRNA levels, for the most part. Bim can be expressed as
three diﬀerent splice variants, an extra long form of Mr
≈24 kDa (BimEL), a long form of Mr ≈21 kDa (BimL),
and a short form of Mr ≈19 kDa (BimS), and CEM cells
express all three of these Bim protein products. As seen in
Figures 5A,B, all three Bim protein products are induced to
some extent following stimulation of cAMP or glucocorticoid
signaling, and the induction is more pronounced (1.6–4.2-
fold stimulation of BimEL) when both signaling pathways are
stimulated together.
As shown in Figure 5C, stimulation of the cAMP signaling
pathway with forskolin and rolipram induced expression of the
mRNA for Bim in MM.1S cells by sevenfold at 4 h, threefold
at 24 h, and ﬁvefold at 48 h. Stimulation of the glucocorticoid
pathway by dexamethasone also induced expression of Bim
mRNA in MM.1S cells by 2–3-fold at each of these time
points. When both signaling pathways were activated by adding
forskolin, rolipram, and dexamethasone together, induction of
Bim mRNA was potentiated, resulting in induction of 12-fold at
4 h, eightfold at 24 h, and ninefold at 48 h (Figure 5C). Analysis
of the eﬀects of these agents on Bim mRNA transcript in MM.1R
cells showed that stimulation of the cAMP signaling pathway with
forskolin and rolipram also induced Bim mRNA expression in
these cells, by 13-fold at 4 h, twofold at 24 h, and fourfold at 48 h
(Figure 5D). However, in contrast to MM.1S cells, and in contrast
to the eﬀects of cAMP signaling, stimulation of the glucocorticoid
signaling pathway with dexamethasone in MM.1R cells had no
eﬀect at all on the expression of Bim mRNA, and little or no
eﬀect on the induction seen in response to forskolin and rolipram
(Figure 5D).
In contrast to CEM (Figures 5A,B) and Hut78 (data not
shown) T leukemic cell lines, which visibly express all three
forms of Bim protein, expression of BimS in MM.1 cells was far
less than that of BimEL and BimL and was only detectable if
the Western blots were greatly overexposed (data not shown).
In MM.1S cells, expression of the BimEL and BimL splice
variants were induced at most of the time points measured,
4, 24, 48, and 72 h, in response to dexamethasone, forskolin
plus rolipram, or all three agents added together (Figure 5C).
However, induction of Bim protein inMM.1S cells was somewhat
higher following stimulation of the cAMP signaling pathway
alone (2–4.7-fold) than following concurrent stimulation of the
cAMP and glucocorticoid signaling pathways (1.2–3.6-fold), and
at all time points examined stimulation of the glucocorticoid
signaling pathway actually attenuated the induction eﬀect of
cAMP on Bim protein expression. In contrast to MM.1S cells,
in MM.1R cells, there was little change in the expression of
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FIGURE 3 | Glucocorticoid receptor (GR) expression in CEM and MM.1 cells. (A,B,E) Quantitative real-time PCR analysis of GR mRNA expression in CEM-S2
(A), CEM-R8 (B), and MM.1S (E) cells, following treatment with 1 µM dexamethasone (Dex), 10 µM rolipram plus 10 µM forskolin (R+F), or 1 µM dexamethasone
plus 10 µM rolipram plus 10 µM forskolin (R+F+D) at different times as indicated. Data represent the mean ± SD of at least two independent experiments assayed
in triplicate, shown as fold change relative to control. (C,D,F) Western blot analysis of GR protein expression in CEM-S2 (C), CEM-R8 (D), and MM.1S (F) cells
following treatment at different times with dexamethasone and/or rolipram and forskolin as indicated. Equal amounts of protein (20 µg) from whole cell lysates were
added per lane. Data shown represents one of at least two independent experiments with similar results. The numbers at the top of the Western blot images
represent the GR band densities following different treatments relative to control, normalized based on the density of the GAPDH housekeeping protein, calculated
as described in Section “Materials and Methods.”
BimEL and BimL following stimulation of the cAMP and
glucocorticoid signaling pathways, either alone or together
(Figure 5D).
Bad Expression is Little Changed in CEM
Cells in Response to Stimulation of the
cAMP and Glucocorticoid Signaling
Pathways, but is Highly Induced in MM.1
Cells
RNA transcript and protein expression for the BH3-only
proapoptotic protein, Bad, was examined by qRT-PCR and
Western blot analysis in response to stimulation of the cAMP
and glucocorticoid signaling pathways. As shown in Figure 6A,
in CEM-S2 cells, stimulation of the glucocorticoid signaling
pathway with dexamethasone produced no eﬀect on Bad mRNA
expression at any time point examined, and stimulation of the
cAMP signaling pathway with forskolin and rolipram produced
a small increase in Bad mRNA expression, about 1.5-fold, only at
the 24 h time point, with or without dexamethasone. Similarly,
as shown in Figure 6B, in CEM-R8 cells, stimulation of either
the cAMP or glucocorticoid signaling pathways produced little
change in BadmRNA expression, although combined stimulation
of the glucocorticoid and cAMP signaling pathways produced a
5–6-fold increase in the expression of BadmRNA at the 4 and 6 h
time points. Also as shown in Figures 6A,B, expression of total
Bad protein in CEM cells was also little aﬀected by these signaling
pathways. Stimulation of the glucocorticoid and cAMP signaling
pathways produced only very small increases in the expression
of total Bad protein, seen mostly at the 4 h time point, where
in CEM-S2 cells, Bad protein increased 1.5-fold in response to
dexamethasone, 1.7-fold in response to forskolin plus rolipram,
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FIGURE 4 | Glucocorticoid receptor alpha (GR) promoter 1A, 1B, and 1C expression in CEM and MM.1 cells. Quantitative real-time PCR analysis of
GR1A3, 1B and 1C mRNA expression in both CEM and MM.1 cells. (A), GR1A3(i), 1B(ii), and 1C(iii) expression in CEM-S2 cells. (B), GR1A3(i), 1B(ii), and 1C(iii)
expression in CEM-R8 cells. (C), GR1A3(i), 1B(ii), and 1C(iii) expression in MM.1S cells. Points were taken following treatment with 1 µM dexamethasone (Dex),
10 µM rolipram plus 10 µM forskolin (R+F), or 1 µM dexamethasone plus 10 µM rolipram plus 10 µM forskolin (R+F+D) for different times as indicated. Data
represent the mean ± SD of at least two independent experiments assayed in triplicate.
and 1.9-fold when all three agents were added together. In CEM-
R8 cells at 4 h Bad protein increased 1.2-fold in response to
dexamethasone, 1.2-fold in response to forskolin plus rolipram,
and 1.4-fold when all three agents were added together.
In MM.1S and MM.1R cells, as shown in Figures 6C,D,
stimulation of the glucocorticoid signaling pathway alone by
dexamethasone had no eﬀect on expression of the mRNA for
Bad at any of the time points measured. Stimulation of the
cAMP pathway with forskolin and rolipram resulted in a small
upregulation of Bad mRNA, ranging from 1.3 to 1.5-fold in
MM.1S cells and 1.6–2.2-fold in MM.1R cells at the diﬀerent time
points measured. Addition of dexamethasone to forskolin and
rolipram produced no further change in Bad mRNA expression
in MM.1R cells, but potentiated the eﬀects of cAMP signaling
in MM.1S cells, such that the expression levels of Bad mRNA in
MM.1S cells were increased to 2.2-fold at 4 h, twofold at 24 h, and
fourfold at 48 h (Figures 6C,D).
Western blot analysis of total Bad protein revealed appreciable
increases in expression in MM.1S cells in response to stimulation
of cAMP and glucocorticoid signaling. Bad protein expression
increased 1.1–1.7-fold by independent stimulation of the cAMP
or glucocorticoid signaling pathways at 4 h and 24 h, and
increased further to 2.2-fold at 24 h when both signaling
pathways were stimulated by addition of dexamethasone and
forskolin plus rolipram together (Figure 6C). At 48 h, expression
of Bad protein was increased 1.9-fold by dexamethasone and
twofold by forskolin plus rolipram treatment, and its expression
was increased further to fourfold when all three agents were
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FIGURE 5 | Bim expression in CEM and MM.1 cells. (A) Quantitative real-time PCR analysis of Bim mRNA expression in CEM-S2 cells (top), at different times
following treatment with 1 µM dexamethasone (Dex), 10 µM rolipram plus 10 µM forskolin (R+F) or 1 µM dexamethasone plus 10 µM rolipram plus 10 µM forskolin
(R+F+D) as indicated. Data represent the mean ± SD of at least two independent experiments assayed in triplicate, shown as fold change relative to control.
(bottom), Western blot analysis of expression of Bim protein. Cells were treated at different times with dexamethasone and/or rolipram and forskolin as indicated,
and Bim protein expression was determined by immunoblots of whole cell lysates. Equal amounts of protein (20 µg) were loaded per lane. Data shown represents
one of at least two independent experiments with similar results. The numbers at the top of the Western blot images represent the BimEL band densities following
different treatments relative to control, normalized based on the density of the GAPDH housekeeping protein, calculated as described in Section “Materials and
Methods.” (B) CEM-R8 cell Bim mRNA (top) and protein (bottom) expression. (C) Bim mRNA (top) and protein (bottom) expression in MM.1S cells. (D) Bim mRNA
(top) and protein (bottom) expression in MM.1R cells. Conditions were as in (A).
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FIGURE 6 | Bad expression in CEM and MM.1 cells. Top panels: quantitative real-time PCR analysis of Bad mRNA at different times after treatment with 1 µM
dexamethasone (Dex), 10 µM rolipram plus 10 µM forskolin (R+F), or 1 µM dexamethasone plus 10 µM rolipram plus 10 µM forskolin (R+F+D) as indicated. Data
represent the mean ± SD of at least two independent experiments assayed in triplicate, shown as fold change relative to control. Bottom panels: Western blot
analysis of expression of total Bad and p-Bad (ser112) protein. Cells were treated at different times with dexamethasone and/or rolipram and forskolin as indicated,
and Bad protein expression was determined by immunoblots of whole cell lysates. An equal amount of protein (20 µg) was loaded per lane. Densities of
phosphorylated Bad (P) and total Bad (T) are given at the top of the Western blot panels, calculated as described in Section “Materials and Methods.” Data shown
represents one of at least two independent experiments with similar results. (A) CEM-S2 cells; (B) CEM-R8 cells; (C) MM.1S cells, and (D) MM.1R cells.
added together to stimulate both signaling pathways (Figure 6C).
At 72 h, Bad expression was increased 2.5-fold by dexamethasone,
3.2-fold by forskolin plus rolipram, and 3.4-fold when all three
agents were added together (Figure 6C). Similarly, in MM.1R
cells, Bad expression was also induced by stimulation of these
signaling pathways, with the largest eﬀects seen at 72 h, where Bad
expression was increased 1.4-fold by dexamethasone, 3.3-fold by
forskolin plus rolipram, and 3.5-fold by all three agents added
together (Figure 6D). Hence, although total Bad protein is little
changed in CEM-S2 and CEM-R8 cells in response to stimulation
of cAMP and glucocorticoid signaling, it is considerably induced
in MM.1 cells, both in the MM.1S sensitive and MM.1R resistant
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cells, both by stimulation of the cAMP and glucocorticoid
signaling pathways independently, and to an even greater extent
when both signaling pathways are stimulated together.
Stimulation of the cAMP Signaling
Pathway Alters the Phosphorylation
State of Bad in Glucocorticoid-Sensitive
and Resistant CEM and MM.1 Cells
The activity of Bad, as a proapoptotic protein, is regulated by its
state of phosphorylation. Phosphorylation of Bad on several sites,
especially Ser112, promotes its association with 14-3-3 protein
and sequesters it in an inactive state. Dephosphorylation of Bad
at these sites promotes its dissociation from 14-3-3 allowing it
to interact with mitochondria and promote apoptosis (Chiang
et al., 2001; Moon and Lerner, 2003). We therefore investigated
the state of phosphorylation of Bad following stimulation of
the glucocorticoid and cAMP signaling pathways. As shown
in Figures 6A,B, although there was little change in total
Bad protein in CEM cells following stimulation of the cAMP
and glucocorticoid pathways, stimulation of these two signaling
pathways together resulted in dephosphorylation of Bad at ser112
in both the glucocorticoid-sensitive and resistant CEM cell
lines. Additionally, very similar to the eﬀect seen with CEM
cells, stimulation of the cAMP and glucocorticoid signaling
pathways also led to a dramatic dephosphorylation of Bad on
ser112 in both the MM.1S and MM.1R cells (Figures 6C,D).
Hence, one common result of the stimulation of the cAMP and
glucocorticoid pathways in both the glucocorticoid-sensitive and
resistant CEM and glucocorticoid-sensitive and resistant MM.1
cells is the activation of Bad via its dephosphorylation on ser112.
Model for the Synergy between cAMP
and Glucocorticoid Signaling Pathways
on Induction of Apoptosis in Leukemic
and Multiple Myeloma Cells
A model for how cAMP and glucocorticoid signaling might
synergize with each other to induce apoptosis and overcome
glucocorticoid resistance in these cells is presented in Figure 7.
In this model it is proposed that glucocorticoids upregulate
the expression of Bim through a Fox03a-dependent mechanism.
Phosphodiesterase inhibitors, such as the PDE4 inhibitor
rolipram, or agents that activate adenylyl cyclase through G
protein coupled receptors, stimulate cAMP signaling which can
lead to activation of the protein phosphatase 2A. The activated
protein phosphatase 2A then dephosphorylates Bad on ser112,
resulting in its dissociation from 14-3-3 chaperone protein and
its translocation to the mitochondria, where it acts as a sensitizer
by binding to antiapoptotic proteins such as Bcl-2 in leukemic
cells andMcl-1 inmultiple myeloma cells, and releasing Bim from
its association with these proteins. The released Bim then binds
to Bax and the complex acts to permeabilize the mitochondrial
membrane, leading to apoptosis. In some cells, as shown in
this study for the MM.1S and MM.1R multiple myeloma cells,
the increased cAMP signaling not only activates Bad, but also
upregulates its expression. Further, the increased cAMP can
also inhibit the growth promoting kinase, Akt, which disinhibits
Fox03a, leading to further upregulation of Bim. The increased
Bim, as an activator protein, primes the cells for death in response
to the translocation of the dephosphorylated, activated Bad
sensitizer protein to the mitochondria, leading to a synergistic
induction of apoptosis and overcoming glucocorticoid resistance.
DISCUSSION
Resistance to glucocorticoids is a major problem in the treatment
of leukemia and multiple myeloma (Haarman et al., 2003;
Frankfurt and Rosen, 2004; Schmidt et al., 2004; Ploner
et al., 2005; Sionov et al., 2008; Bhadri et al., 2012). In
this study we investigated changes in GR, and the BH3-only
proapoptotic proteins, Bim and Bad, in cell line models of
glucocorticoid-sensitive and resistant leukemia and multiple
myeloma. Consistent with other reports (Krett et al., 1997;
Medh et al., 1998; Ogawa et al., 2002; Tiwari et al., 2005;
Lerner and Epstein, 2006; Dong et al., 2010; Follin-Arbelet
et al., 2011) in the cell models we examined here, we found
that both the glucocorticoid-sensitive and resistant leukemia and
multiple myeloma cell lines could be killed by stimulation of
the cAMP signaling pathway, and that stimulation of the cAMP
signaling pathway acted synergistically with glucocorticoids
to induce cell death of both the glucocorticoid-sensitive and
resistant CEM leukemic cell lines and the glucocorticoid-sensitive
MM.1S multiple myeloma cell line. A synergistic eﬀect of cAMP
and glucocorticoid signaling was not seen with the MM.1R,
glucocorticoid-resistant cell line, most likely as a result of the
MM.1R cell line expressing a truncated form of GR (Moalli et al.,
1992).
Although loss or mutations in GR occur in a number of
glucocorticoid-resistant cell lines, this only rarely occurs in
primary cells from most patients, and thus appears not to
account for the prevalence of glucocorticoid-resistance seen in
patients treated with glucocorticoids (Bachmann et al., 2005,
2007; Tissing et al., 2006; Beesley et al., 2009). We examined
changes in the expression of GR mRNA, GR promoters, and
GR protein in glucocorticoid-sensitive and resistant leukemia
and multiple myeloma cells in response to stimulation of cAMP
and glucocorticoid signaling in these cells, and examined the
correlation of these changes with induction of cell death in
these cells following stimulation of these signaling pathways.
Most cell types demonstrate down regulation of GR following
glucocorticoid exposure, presumably as a feedback mechanism,
although GR in some lymphoid leukemia cell lines has been
reported to be upregulated (Tissing et al., 2006). It has also been
observed in some cell lines that dexamethasone can dramatically
alter GR protein levels without changing GR mRNA expression,
leading to the suggestion that glucocorticoids may inﬂuence GR
protein levels by other means besides transcriptional regulation,
such as mRNA and GR protein stability (Okret et al., 1991).
Eﬀects of cAMP signaling on GR expression are also complex
and can lead either to upregulation (Oikarinen et al., 1984; Dong
et al., 1988) or down regulation (Sheppard et al., 1991) depending
on the cell type. A study from the Lerner laboratory showed
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FIGURE 7 | Model for the synergy between cAMP and glucocorticoid signaling pathways on induction of apoptosis in leukemic and multiple
myeloma cells. GC, glucocorticoids; GPCR, G protein coupled receptor; PP2A, protein phosphatase 2A; PDE4, phosphodiesterase4; GRE,
glucocorticoid-responsive element.
that stimulation of the cAMP signaling pathway with PDE4
inhibitors upregulated GR transcript levels in B-CLL cells but
not T-CLL cells, Sezary cells or normal circulating T or B cells,
monocytes, or neutrophils (Meyers et al., 2007). In this same
study, it was shown that glucocorticoids reduce GR mRNA levels
in B-CLL and that co-treatment with PDE4 inhibitors maintains
GR mRNA levels above baseline. In our current study, although
we see some increased expression of GR mRNA following
stimulation of cAMP and glucocorticoid signaling, we see almost
no change, only very small modest increases in GR protein at
later time points, in both glucocorticoid-sensitive CEM-S2 and
glucocorticoid-resistant CEM-R8 cells following stimulation of
either cAMP signaling, stimulation of glucocorticoid signaling,
or stimulation of both signaling pathways together. In contrast,
in the MM.1S multiple myeloma cells, which are of B cell origin,
stimulation of glucocorticoid signaling with dexamethasone
greatly down regulated GR protein. However, unlike that seen
in the B-CLL cells, co-stimulation of the cAMP signaling
pathway enhanced this down regulation, rather than preventing
it, leading to a profound reduction in the expression of
GR.
Results from this study indicate that the cell death induced
by cAMP signaling in these cells and the potentiation of
glucocorticoid-induced cell death by cAMP signaling does not
correlate with increased expression of GR protein, suggesting that
the actions of these signaling pathways on viability of these cells
is not mediated by changes in expression of GR. However, it is
possible that alterations in GR may still play a role in the actions
of these signaling pathways at the post-translational level, since
GR has been shown to be a substrate for PKA (Haske et al.,
1994), and thus its actions could be modiﬁed by cAMP signaling.
Further, there is some evidence to suggest that translocation
of GR from the cytosol to mitochondria may also play a role
in mediating cell death (Sionov et al., 2006), and it is possible
that this translocation could be inﬂuenced by these signaling
pathways. Additionally, we found that cAMP signaling induced
expression of the GR promoters in glucocorticoid-sensitive and
resistant CEM cells and glucocorticoid-sensitive MM.1 cells, with
induction of the 1A3 promoter stimulated more than 1B and 1C,
and with further potentiation of this eﬀect by dexamethasone in
CEM cells. cAMP signaling was also shown to increase levels of
the 1A3 promoter to a greater extent than the 1B promoter in
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B-CLL cells as well (Meyers et al., 2007). Inasmuch as expression
of GR from the 1A promoter correlates best with T lymphocyte
sensitivity to glucocorticoid-induced cell death (Purton et al.,
2004), a shift to expression of more of the GR from the 1A3
promoter, relative to its expression from the other promoters,
might also contribute to the cAMP sensitivity of these cells.
A number of studies have pointed to Bim as being an essential
mediator of glucocorticoid-induced apoptosis of leukemic,
lymphoma and myeloma cells, in that Bim is upregulated in these
cells following glucocorticoid treatment, and down regulation of
the expression of Bim inhibits glucocorticoid-induced apoptosis
(Wang et al., 2003; Abrams et al., 2004; Bachmann et al., 2005;
Ploner et al., 2005; Lu et al., 2006; Iglesias-Serret et al., 2007;
Lopez-Royuela et al., 2010; Jiang et al., 2011; Zhao et al., 2011;
Heidari et al., 2012; Jing et al., 2015). Additionally, stimulation of
the cAMP signaling pathway has also been shown to upregulate
Bim and induce apoptosis in leukemic and lymphoma cells
(Meyers et al., 2009; Huseby et al., 2011; Zambon et al., 2011).
cAMP signaling also upregulates Bim in normal T and B
lymphocytes, but of note, in contrast to leukemic cells, the
upregulation of Bim in normal lymphoid cells in response to
cAMP signaling does not lead to apoptosis (Meyers et al., 2009).
It was reported that stimulation of cAMP signaling enhanced
dexamethasone upregulation of Bim and promoted increased
apoptosis of leukemic and lymphoma cells, suggesting that
Bim may be a convergence point for the increased response
seen when these two signaling pathways are stimulated (Zhang
and Insel, 2004). Our results conﬁrm this and also point to
increased upregulation of Bim as being a possible convergence
point for the synergistic eﬀects of cAMP and glucocorticoid
signaling on inducing apoptosis of the glucocorticoid-sensitive
CEM-S2 and glucocorticoid-resistant CEM-R8 cells that we
employed in this study. However, we did not see evidence for
this in multiple myeloma cells. In the glucocorticoid-sensitive
MM.1Smyeloma cells, although stimulation of the glucocorticoid
and cAMP signaling pathways both stimulated upregulation
of Bim protein expression, there was no further enhanced
expression of Bim protein when both signaling pathways were
stimulated together, even though there was enhanced promotion
of apoptosis when both signaling pathways were stimulated. And
in the glucocorticoid-resistant MM.1R myeloma cell line, no
upregulation of Bim protein expression was seen in response to
glucocorticoid signaling, cAMP signaling, or stimulation of both
signaling pathways together. Inasmuch as cAMP signaling clearly
induced apoptosis of MM.1R cells, our ﬁndings suggest that a
mechanism(s) other than Bim induction must come into play
to account for the apoptosis that results in response to cAMP
stimulation in these cells.
Studies from the Lerner laboratory had shown that stimulation
of the cAMP signaling pathway with rolipram and forskolin
led to activation of protein phosphatase 2A, dephosphorylation
of Bad on ser112, and translocation of Bad to mitochondria,
suggesting that activation of the proapoptotic protein Bad may
also be important for apoptosis induced by cAMP signaling
(Moon and Lerner, 2003). In this study we saw little upregulation
of total Bad protein in either CEM-S2 or CEM-R8 cells, but
we saw considerable upregulation of Bad protein in both the
MM1.S and MM1.R multiple myeloma cells. Moreover, we
observed dephosphorylation of Bad on ser112 in response to
stimulation of cAMP signaling in all cell types studied here, CEM-
S2, CEM-R8, MM.1S and MM.1R, and this dephosphorylation
was greatly potentiated by stimulation of the glucocorticoid
pathway concurrent with the cAMP signaling pathway. These
results suggest that Bad may be an important mediator of
apoptosis inmultiple myeloma cells in response to these signaling
pathways, and that dephosphorylation and activation of Badmay
also be a convergence point for induction of apoptosis by the
glucocorticoid and cAMP signaling pathways.
Studies have shown that the ability of glucocorticoids to
induce apoptosis of leukemic cells may depend in part on
the relative balance of the proapoptotic protein Bim and the
antiapoptotic protein Bcl-2 present in the target cell (Ploner et al.,
2005; Jing et al., 2015), and the same may be true for Bim and the
antiapoptotic protein Mcl-1 in multiple myeloma cells (Gomez-
Bougie et al., 2004; Follin-Arbelet et al., 2013). Models put forth
by the Letai laboratory describe Bim as an activator protein,
capable of binding directly to Bax, resulting in mitochondrial
membrane permeabilization, whereas Bad is described as a
sensitizer protein capable of binding to antiapoptotic proteins
like Bcl-2 and Mcl-1, which thus frees Bim from its tethered
association with Bcl-2 or Mcl-1, allowing it to bind Bax
and initiate permeabilization of the mitochondrial membrane
(Brunelle and Letai, 2009). Cells in which activator proteins such
as Bim are in higher abundance may be primed for death by
being particularly sensitive to exposure to sensitizer domains
provided by Bad, such that an increase in Bad may tip the
balance and induce apoptosis. Inasmuch as Bad was induced
in MM.1S and MM.1R cells, as well as dephosphorylated on
ser112, in response to cAMP signaling, this may in part explain
the mechanism whereby cAMP signaling induces apoptosis in
multiple myeloma. Small molecule BH3-mimetics that mimic the
BH3 binding domain of proapoptotic proteins such as Bad have
been found to be eﬀective inducers of apoptosis, and at least one
such BH3-mimetic, ABT-199, has been entered into clinical trials
for treatment of multiple myeloma, as well as for lymphomas
and leukemias (Correia et al., 2015). Our results presented in
this study would suggest that stimulation of the cAMP signaling
pathway with PDE inhibitors in conjunction with BH3-mimetics
may well provide an even more eﬀective therapeutic strategy for
treatment of leukemia and multiple myeloma.
Several studies have shown altered expression of PDEs
in leukemic patients to be associated with poorer treatment
outcomes, often related to glucocorticoid resistance in the
treatment of these patients. For example, CLL patients with
higher expression levels of PDE7B have a several-year shorter
median time-to-treatment compared to patients with lower
levels of PDE7B expression (Zhang et al., 2011). Overexpression
of PDE4B in patients with diﬀuse large B cell lymphoma
(DLBCL) was associated with relapse after chemotherapy, and
overexpression of PDE4B in DLBCL impinged on the same
genes that are normally active in glucocorticoid resistance (Smith
et al., 2005; Kim et al., 2011). A study of 2,535 children with
ALL showed single nucleotide polymorphisms in the PDE4B
gene to be associated with a high risk of relapse in children
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newly diagnosed with ALL, and it was suggested that this may
be due to the resultant glucocorticoid resistance that develops
due to the PDE4B polymorphisms, which further underscores
the importance of targeting PDE4 in overcoming glucocorticoid
resistance (Yang et al., 2012). When high throughput screening
technology was employed to identify agents that synergize
with dexamethasone to inhibit proliferation of MM.1S and
DLBCL cells, the compounds identiﬁed to produce the greatest
amount of synergy were adenosine A2A receptor agonists and
PDE 2,3,4, and 7 inhibitors (Rickles et al., 2010). In a study
examining the in vitro antileukemic activity of 20 diﬀerent
anticancer agents against tumor cells from CLL patients aimed
at identifying agents active in poor-prognostic subgroups, it
was found that prednisolone and rolipram displayed high CLL
speciﬁcity and high activity in CLL with unmutated IGHV
genes and when prednisolone and rolipram were combined they
displayed considerable synergy against these CLL cells, thereby
identifying rolipram as an agent with high activity in cells from
patients with poor prognosis (Lindhagen et al., 2009). Recent
studies from the Lerner laboratory showed that rolipram induced
apoptosis of both IGHV unmutated and mutated CLL cells,
suggesting that cAMP signaling may abrogate a TLR9-mediated
survival signal in prognostically unfavorable IGHV unmutated
CLL cells, and indicating that PDE4 inhibitors may well be of
clinical utility in CLL or autoimmune diseases that are driven
by TLR-mediated signaling (Tan et al., 2015). PDE inhibitors are
currently under intense development for a wide range of illnesses
and are rapidly being approved for clinical use (Houslay et al.,
2005; Bender and Beavo, 2006; Lugnier, 2006; Epstein, 2012;
Maurice et al., 2014; Ahmad et al., 2015). Of note, two PDE4
inhibitors, roﬂumilast and apremilast, are already approved
and in clinical use for the indications of chronic obstructive
pulmonary disease and psoriatic arthritis, respectively. These
studies, as well as the results of our study presented here, suggest
that PDE inhibitors may provide valuable tools for overcoming
glucocorticoid resistance and thereby improve the treatment
outcome of patients with lymphomas, leukemias, and multiple
myeloma. As such, clinical studies should clearly be undertaken
with PDE inhibitors, either as single agents, or in combination
with BH3-mimetics and/or established therapeutic agents for
treatment of patients with leukemia, lymphoma and multiple
myeloma in relation to glucocorticoid resistance.
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